EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial

Dirk J van Veldhuisen, Michiel Rienstra, Arend Mosterd, A Marco Alings, Antoinette D J van Asselt, Marcel L Bouvy, Jan G P Tijssen, Jeroen Schaap, Ernst E van der Wall, Adriaan A Voors, Eva M Boorsma, Dirk J A Lok und 11 weitere

European Journal of Heart Failure · 01.10.2024 · 26 (10) · 2223-2230

DOI: 10.1002/ejhf.3428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 30.08.2024. Verfasst von Dirk J van Veldhuisen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Digoxin, Heart Failure, Cardiotonic Agents, Stroke Volume. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low-dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment.

Methods

The DECISION trial is a randomized, double-blind, parallel-group, placebo-controlled event-driven outcome trial which will investigate the efficacy and safety of low-dose digoxin in patients with chronic HF and LVEF <50%. Both patients with sinus rhythm and atrial fibrillation will be enrolled and will be randomized (1:1) to low-dose digoxin or matching placebo. To maintain a target serum digoxin concentration of 0.5–0.9 ng/ml, dose adjustments are made throughout follow-up based on serum digoxin measurements with dummy values for the placebo group. The primary endpoint is a composite of CV mortality and total HF hospitalizations or total urgent hospital visits for worsening HF, and all endpoints are adjudicated blindly by a Clinical Event Committee. The estimated sample size was 982 patients who will be followed for a median of 3 years, and in December 2023 enrolment was completed after 1002 patients.

Conclusions

The DECISION trial will provide important evidence regarding the effect of (low-dose) digoxin on CV mortality and total HF hospitalizations and urgent hospital visits when added to contemporary HF treatment of patients with reduced or mildly reduced LVEF. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03783429.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DigoxinHeart FailureCardiotonic AgentsStroke VolumeHumansDouble-Blind MethodFemaleMaleVentricular Function, LeftTreatment OutcomeHospitalizationDose-Response Relationship, DrugAgedNetherlandsMiddle AgedRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

DigoxinHeart failureHospitalizationsLow‐doseMortalityRandomized clinical trial

Substanzen

DigoxinCardiotonic Agents

Autor:innen und Institutionen

  • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Cardiology, Meander Medisch Centrum, Amersfoort, The Netherlands.
  • Workgroup Cardiology Centers, Utrecht, The Netherlands.
  • Department of Cardiology, Amphia Medical Center, Breda, The Netherlands.
  • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Zitieren

APA

van Veldhuisen, D. J., Rienstra, M., Mosterd, A., Alings, A. M., van Asselt, A. D. J., Bouvy, M. L., Tijssen, J. G. P., Schaap, J., van der Wall, E. E., Voors, A. A., Boorsma, E. M., Lok, D. J. A., Crijns, H. J. G. M., Schut, A., Vijver, M. A. T., Voordes, G. H. D., de Vos, A. H., Maas-Soer, E. L., Smit, N. W., …, & DECISION Investigators and Committees (2024). Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial. European Journal of Heart Failure, 26(10), 2223-2230. https://doi.org/10.1002/ejhf.3428

Vancouver

van Veldhuisen DJ, Rienstra M, Mosterd A, Alings AM, van Asselt ADJ, Bouvy ML, et al. Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial. European Journal of Heart Failure. 2024;26(10):2223-2230. doi:10.1002/ejhf.3428

BibTeX
@article{vanVeldhuisen2024,
  author = {van Veldhuisen, Dirk J and Rienstra, Michiel and Mosterd, Arend and Alings, A Marco and van Asselt, Antoinette D J and Bouvy, Marcel L and Tijssen, Jan G P and Schaap, Jeroen and van der Wall, Ernst E and Voors, Adriaan A and Boorsma, Eva M and Lok, Dirk J A and Crijns, Harry J G M and Schut, Astrid and Vijver, Marlene A T and Voordes, Geert H D and de Vos, Agaath H and Maas-Soer, Ester L and Smit, Nicoline W and Touw, Daan J and Samuel, Michelle and van der Meer, Peter and DECISION Investigators and Committees, DECISION Investigators and Committees},
  title = {Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {2223--2230},
  doi = {10.1002/ejhf.3428}
}
Kostenlos starten →